Log In
BCIQ
Print this Print this
 

HTI-1403

  Manage Alerts
Collapse Summary General Information
Company Jiangsu Hengrui Medicine Co. Ltd.
DescriptionAntibody-drug conjugate comprising a receptor tyrosine kinase antibody conjugated to a toxin
Molecular Target Receptor tyrosine kinase (RTK)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat RTK-positive advanced tumors
Regulatory Designation
PartnerHengrui Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today